The world of lobbying: Quickel joins Hollier & Associates, Crapo alumni reunite

mike quikelformer policy director and longtime tax and budget policy advisor to Sen. Mike Crapo (R-Idaho). I participated Hollier & Associates As a partner. The move reunites Mr. Quickle with Will Hollier, Mr. Crapo’s former chief of staff and founder of a lobbying firm.

ed hill I am joining Forbes Tate Partners As a partner in the company’s government relations work. Mr. Hill most recently served as senior vice president and director of government affairs for the Banking Policy Institute, a lobbying and advocacy group for the financial services industry.

Dr. wendy summons jackson serves on the federal government relations team of Essential government work. A retired U.S. Army colonel, she most recently served as Deputy Chief of Staff for Research and Technology at the U.S. Army Medical Research and Development Command (USAMRDC).

Tiber Creek Group hired nicole burrows As a partner. Burrows most recently served as deputy chief of staff at the United States Agency for International Development (USAID).

katie mahoney is participating in Healthcare Leadership Council (HLC) as Executive Vice President and Chief Policy Officer. She comes to HLC from the U.S. Chamber of Commerce, where she most recently served as vice president for health policy.

Will Anderson is returning to business round table Appointed as Vice President in charge of Corporate Governance. He most recently served as staff director for the Capital Markets Subcommittee of the House Financial Services Committee.

Sarah Puro I am joining Alliance for Automotive Innovation Appointed as Vice President for Safety and Technology Policy. Mr. Puro most recently served as senior advisor to National Transportation Safety Board Chair Jennifer Homendy.

Patrick Kane I participated in film association Appointed as Vice President of Digital Strategy. He previously served as Head of Digital at the British Embassy.

Lo Isidro I participated narrative strategy As a senior director. He most recently served as senior director of Real Chemistry, and is also an alumnus of Stand Together, Americans for Prosperity, and Capitol Hill.

Chairman and CEO, Gilead Sciences Daniel O’Day new chair Pharmaceutical Research and Manufacturers of America (PhRMA) board of directors. Mr. O’Day will succeed Novartis CEO Basu Narasimhan as Chairman of the Board. Pfizer Chairman and CEO Albert Bourla Appointed as the next chairman, paul hudsonSanofi’s CEO will serve as financial director.